Neuronetics, Inc.·4

Jul 5, 4:32 PM ET

Farley Brian E 4

4 · Neuronetics, Inc. · Filed Jul 5, 2018

Insider Transaction Report

Form 4
Period: 2018-07-02
Transactions
  • Conversion

    Common Stock

    2018-07-02+8,48384,065 total
  • Conversion

    Common Stock

    2018-07-02+15,34299,407 total
  • Conversion

    Common Stock

    2018-07-02+1,506110,438 total
  • Conversion

    Series D Covertible Preferred Stock

    2018-07-028,4830 total
    Common Stock (8,483 underlying)
  • Conversion

    Series E Covertible Preferred Stock

    2018-07-0215,3420 total
    Common Stock (15,342 underlying)
  • Conversion

    Series F Covertible Preferred Stock

    2018-07-029,5250 total
    Common Stock (9,525 underlying)
  • Conversion

    Series G Covertible Preferred Stock

    2018-07-021,5060 total
    Common Stock (1,506 underlying)
  • Conversion

    Common Stock

    2018-07-02+9,525108,932 total
  • Award

    Stock Option Grant (Right to Buy)

    2018-07-02+10,95910,959 total
    Exercise: $5.22Exp: 2028-04-25Common Stock (10,959 underlying)
Footnotes (2)
  • [F1]Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering.
  • [F2]The performance criterion for vesting of this option was met upon the closing of the Issuer's initial public offering. One twelfth (1/12th) of the shares subject to the option vested or shall vest monthly commencing on March 16, 2018, subject to Reporting Person continuing to provide service through each such date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION